血管内皮生长因子与肾细胞癌  

Vascular endothelial growth factor and renal cell carcinoma

作　　者：周术奎[1] 王顺平[1] 王跃闽[1] 

机构地区：[1]同济大学附属东方医院泌尿外科,上海200120

出　　处：《国际肿瘤学杂志》2012年第2期148-151,共4页Journal of International Oncology

摘　　要：血管内皮生长因子（VEGF）在肾细胞癌组织中高表达，主要受VHL基因和组织缺氧调控，可作为判断肾细胞癌患者肿瘤进展和预后的标志物。近年来将抗VEGF靶向药物用于肾细胞癌治疗，取得良好的临床疗效。Vascular endothelial growth factor（VEGF） is high expressed in the organization of renal cell carcinoma and is mainly regulated by VHL gene and hypoxic of organization. Moreover, it can be used as a biomarker to judge renal cell carcinoma tumor progression and prognostic. In recent years, anti-VEGF targeted drugs are used for the treatment of renal cell carcinoma and receive meaningful clinical benefits.

关 键 词：血管内皮生长因子类 肾肿瘤 治疗应用 

分 类 号：R737.11[医药卫生—肿瘤]